NCT03179436
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase
Exclusions: Patients with known untreated central nervous system (CNS) metastases or leptomeningeal disease
https://ClinicalTrials.gov/show/NCT03179436